Re: [Commons-Law] Who Will Pay for This?
Via: Lawrence Liang
maybe you should read
http://www.amazon.com/800-Million-Pill-Truth-behind/dp/0520239458 for
an answer
Lawrence
Hasit seth wrote:
> Who will pay for this? Cost of a successful drug includes cost of many
> unsuccessful ones. Take note...
>
> NEW YORK (Reuters) -- Pfizer Inc. said on Wednesday it has
> discontinued trials of an experimental lung cancer drug licensed from
> Coley Pharmaceutical Group after an independent review committee
> deemed it ineffective, spurring a 60 percent decline in Coley shares.
>
> "The [committee] concluded that the risk-benefit profile did not
> justify continuation of the trials," Pfizer
>
> (down $0.38 to $25.83, Charts
> ,
> Fortune 500
> )
> said in a press release.
>
> The New York-based drugmaker, which is trying to become a major force
> in oncology, said the canceled trials include two late-stage and two
> mid-stage studies of the medicine, which it licensed from Coley
>
> (down $4.92 to $3.57, Charts
> )
> in 2005.
>
> The compound, called PF-3512676, was no more effective in combination
> with chemotherapy than chemotherapy alone, according to an analysis by
> the independent data safety monitoring committee.
>
> It is Coley's only drug in late-stage trials, making it the company's
> most important drug.
>
> Coley shares were down $5.06 to $3.43 in heavy afternoon trading on
> the Nasdaq. Pfizer was down 44 cents, or 1.6 percent, to $25.77 on the
> New York Stock Exchange, amid a 0.9 percent decline for the American
> Stock Exchange Pharmaceutical Index of large U.S. and European drugmakers.
>
> Cowen and Co. had predicted the medicine, if approved, would generate
> annual sales of $100 million by 2012. Top of page
>
>
>
> ------------------------------------------------------------------------
>
> _______________________________________________
> commons-law mailing list
> commons-law@sarai.net
> https://mail.sarai.net/mailman/listinfo/commons-law
>
maybe you should read
http://www.amazon.com/800-Million-Pill-Truth-behind/dp/0520239458 for
an answer
Lawrence
Hasit seth wrote:
> Who will pay for this? Cost of a successful drug includes cost of many
> unsuccessful ones. Take note...
>
> NEW YORK (Reuters) -- Pfizer Inc. said on Wednesday it has
> discontinued trials of an experimental lung cancer drug licensed from
> Coley Pharmaceutical Group after an independent review committee
> deemed it ineffective, spurring a 60 percent decline in Coley shares.
>
> "The [committee] concluded that the risk-benefit profile did not
> justify continuation of the trials," Pfizer
>
> (down $0.38 to $25.83, Charts
> ,
> Fortune 500
> )
> said in a press release.
>
> The New York-based drugmaker, which is trying to become a major force
> in oncology, said the canceled trials include two late-stage and two
> mid-stage studies of the medicine, which it licensed from Coley
>
> (down $4.92 to $3.57, Charts
> )
> in 2005.
>
> The compound, called PF-3512676, was no more effective in combination
> with chemotherapy than chemotherapy alone, according to an analysis by
> the independent data safety monitoring committee.
>
> It is Coley's only drug in late-stage trials, making it the company's
> most important drug.
>
> Coley shares were down $5.06 to $3.43 in heavy afternoon trading on
> the Nasdaq. Pfizer was down 44 cents, or 1.6 percent, to $25.77 on the
> New York Stock Exchange, amid a 0.9 percent decline for the American
> Stock Exchange Pharmaceutical Index of large U.S. and European drugmakers.
>
> Cowen and Co. had predicted the medicine, if approved, would generate
> annual sales of $100 million by 2012. Top of page
>
>
>
> ------------------------------------------------------------------------
>
> _______________________________________________
> commons-law mailing list
> commons-law@sarai.net
> https://mail.sarai.net/mailman/listinfo/commons-law
>
comments
No new comments allowed (anymore) on this post.